Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to $1.4 million.

  • Arcadia Biosciences' Shares Outstanding (Weighted Average) rose 25.22% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 25.22%. This contributed to the annual value of $1.4 million for FY2024, which is 1021.63% up from last year.
  • Latest data reveals that Arcadia Biosciences reported Shares Outstanding (Weighted Average) of $1.4 million as of Q3 2025, which was up 25.22% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Arcadia Biosciences' Shares Outstanding (Weighted Average) registered a high of $22.2 million during Q3 2021, and its lowest value of $532016.0 during Q4 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $4.3 million, with a median of $1.4 million in 2024.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first plummeted by 9744.9% in 2022, then surged by 14487.81% in 2023.
  • Over the past 5 years, Arcadia Biosciences' Shares Outstanding (Weighted Average) (Quarter) stood at $532016.0 in 2021, then grew by 12.66% to $599389.0 in 2022, then soared by 106.37% to $1.2 million in 2023, then grew by 10.22% to $1.4 million in 2024, then grew by 0.29% to $1.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.